Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kai Wucherpfennig, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Kai Wucherpfennig and Henry Long.
Connection Strength

0.768
  1. Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. J Exp Med. 2020 07 06; 217(7).
    View in: PubMed
    Score: 0.229
  2. Correction: Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. J Exp Med. 2020 07 06; 217(7).
    View in: PubMed
    Score: 0.229
  3. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018 02 16; 359(6377):770-775.
    View in: PubMed
    Score: 0.193
  4. Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. Cancer Discov. 2021 Oct; 11(10):2564-2581.
    View in: PubMed
    Score: 0.061
  5. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell. 2020 06 18; 78(6):1096-1113.e8.
    View in: PubMed
    Score: 0.057
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.